Kitani Kotaro, Okajima Kaoru, Sato Katsuaki, Isono Sayuri, Kimura Hiroki, Ikeda Mitsunori, Inoue Keisuke, Iwama Mitsuru, Tsujie Masanori, Nakayama Tsuyoshi, Fujiwara Yoshinori, Murata Masaru, Yukawa Masao, Ota Yoshio, Inoue Masatoshi
Dept. of Surgery, Kinki University Faculty of Medicine, Nara Hospital.
Gan To Kagaku Ryoho. 2011 Nov;38(12):2122-4.
We reviewed the patients with neoadjuvant chemoradiotherapy (CRT) with S-1 to evaluate the feasibility and effectiveness for locally advanced lower rectal cancer. The CRT regimen consisted of pelvic irradiation (45 Gy in fractions of 1.8 Gy), five days a week. A treatment of oral S-1 (80 mg/m2 per day) on days 1-14 and 22-35 was given during radiotherapy. Patients underwent a curative resection with lateral lymph node resection at 6-8 weeks intervals after neoadjuvant CRT. The response rate on pathological study was 60% (all were grade 2), and no patients had lateral lymph node metastases. Grade 1 or 2 adverse effects occurred in all patients during CRT, but the CRT was achieved in all patients. We found two patients had surgical complications with wound infection and one patient with anastomotic leakage. All complications were improved by conservative treatment. The neoadjuvant CRT was feasible and effective treatment for all patients with locally advanced rectal cancer. We have started a phase II study of the neoadjuvant CRT.
我们回顾了接受S-1新辅助放化疗(CRT)的患者,以评估其对局部晚期低位直肠癌的可行性和有效性。CRT方案包括盆腔照射(45 Gy,每次1.8 Gy,每周5天)。放疗期间,在第1 - 14天和第22 - 35天给予口服S-1(每天80 mg/m²)治疗。新辅助CRT后6 - 8周,患者接受了根治性切除及侧方淋巴结清扫。病理研究的缓解率为60%(均为2级),无患者发生侧方淋巴结转移。CRT期间所有患者均出现1级或2级不良反应,但所有患者均完成了CRT。我们发现2例患者出现手术并发症,包括伤口感染,1例患者出现吻合口漏。所有并发症经保守治疗均得到改善。新辅助CRT对所有局部晚期直肠癌患者是可行且有效的治疗方法。我们已启动新辅助CRT的II期研究。